Dyne Therapeutics (DYN) Stock Price & Analysis

DYN$17.16+0.15 +0.88%
BiotechnologyGrowth Stock
Compare
Market cap$3.22BEnterprise value$2.52BRevenue (TTM)$0Market position—

Score

69
Bullish
Value
55
Quality
53
Growth
100

AI Analysis

Snapshot

Dyne Therapeutics is a growth-led story right now — Growth 100/100 is the pillar doing the heavy lifting (overall 69/100) in Biotechnology. In Biotechnology, that score mix is usable but not one-dimensional. Street targets still imply ~105% upside.

Price History

Bullish (65+)Neutral (45–64)Bearish (<45)

Score Breakdown

Market percentile scores loading…

Value

55
PE Ratio (F)–
PEG Ratio–
Free Cashflow Yield %–
EV/EBITDA Ratio–
Discount vs All Time Peak–
Discount vs 1Y Peak–

Growth

100
Earnings Forecast–
Last 3M Earnings Growth %–
12M Revenue Growth %–
12M Earnings Growth %–
5 YR CAGR % Earnings–
Analyst Price Forecast–

Quality

53
FCF Margin %–
Net Debt / EBITDA–
Operating Margin %–
Operating Margin Growth %–
ROCE %–
Current Ratio–

Financial Summary

Dyne Therapeutics, Inc. (DYN) last printed $17.16. Equity value is $3.22B. Trailing earnings multiple —. The revenue row is reported history. Targets and ratings are on the forecast page.

Financials

2016201720182019202020212022202320242025
$1.37B$506M$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00

About

Dyne Therapeutics, Inc. is a U.S.-based biotechnology firm focused on developing advanced treatments for genetically driven muscle disorders. Utilizing its proprietary FORCE platform, which is engineered to deliver disease-modifying therapeutics, the company is actively engaged in various programs. These initiatives target conditions such as myotonic dystrophy type 1, Duchenne muscular dystrophy, and facioscapulohumeral dystrophy, in addition to other rare skeletal, cardiac, and metabolic muscle diseases. The company was founded in 2017 and maintains its corporate headquarters in Waltham, Massachusetts.

Dyne Therapeutics (DYN) Stock Price & Analysis

DYN price $17.16 +0.15 +0.88%

Ticker
DYN
Price
$17.16
Change
+0.15 +0.88%
Market cap
$3.22B
Forward P/E
60.03
Dividend yield
0.00%
Beta
1.21
Sector
Healthcare
Industry
Biotechnology
Stocklytics score
69
Value
55
Quality
53
Growth
100

Stocklytics score rationale: value 55, quality 53, growth 100.

Insights · Forecast · Financials · Learn

Stocklytics home · Screener